OverviewSuggest Edit

Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear. The Company has developed a proprietary technology that is designed to deliver a drug that is retained in the ear for an extended period of time following a single local administration. Utilizing this technology, Otonomy has advanced multiple product candidates into development and launched its first product, OTIPRIO®.

OTIPRIO is a single-dose, physician-administered antibacterial and the first product approved by the FDA for the treatment of pediatric patients with bilateral otitis media with effusion undergoing ear tube placement.

TypePublic
Founded2008
HQSan Diego, CA, US
Websiteotonomy.com

Latest Updates

Employees (est.) (Dec 2019)49
Revenue (FY, 2020)$273 K(-54%)
Share Price (Mar 2021)$2.5(-3%)
Cybersecurity ratingAMore

Key People/Management at Otonomy

David A. Weber

David A. Weber

Chief Executive Officer, President and Board Member
Carla da Luz Boren

Carla da Luz Boren

General Counsel and Head of Human Resources
Julie D. Burgess

Julie D. Burgess

Vice President, Finance and Administration
Paul E. Cayer

Paul E. Cayer

Chief Financial & Business Officer
David Skarinsky

David Skarinsky

Vice President, Clinical
Barbara M. Finn

Barbara M. Finn

Vice President, Regulatory Affairs and Quality Assurance
Show more

Otonomy Office Locations

Otonomy has an office in San Diego
San Diego, CA, US (HQ)
4796 Executive Dr
Show all (1)

Otonomy Financials and Metrics

Otonomy Revenue

Embed Graph
View revenue for all periods
Otonomy's revenue was reported to be $273 k in FY, 2020
USD

Revenue (FY, 2020)

273.0k

Gross profit (FY, 2020)

(915.0k)

Gross profit margin (FY, 2020), %

(335.2%)

Net income (FY, 2020)

(44.7m)

EBIT (FY, 2020)

(43.5m)

Market capitalization (30-Mar-2021)

120.3m

Closing stock price (30-Mar-2021)

2.5

Cash (31-Dec-2020)

30.8m

EV

104.7m
Otonomy's current market capitalization is $120.3 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

683.0k1.2m745.0k600.0k273.0k

Revenue growth, %

81%(40%)

Cost of goods sold

1.7m3.1m946.0k912.0k1.2m

Gross profit

(981.0k)(1.9m)(201.0k)(312.0k)(915.0k)
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

24.2m18.5m33.6m25.2m30.8m

Accounts Receivable

91.0k107.0k108.0k48.0k

Prepaid Expenses

2.4m2.4m

Inventories

1.4m6.0k227.0k
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

13.7m22.3m16.9m23.2m19.0m21.4m16.3m12.1m16.3m31.0m32.0m54.2m

Accounts Receivable

178.0k76.0k126.0k133.0k14.0k45.0k14.0k68.0k33.0k

Prepaid Expenses

1.5m3.7m2.2m1.5m2.8m

Inventories

1.2m1.2m1.2m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(110.6m)(90.1m)(50.4m)(44.7m)(44.7m)

Depreciation and Amortization

708.0k1.3m1.2m1.1m1.1m

Inventories

(1.4m)153.0k

Accounts Payable

(2.2m)(398.0k)68.0k127.0k(374.0k)
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(27.1m)(71.3m)(11.4m)(25.0m)(37.5m)(12.0m)(23.7m)(33.7m)(11.8m)(23.2m)(34.1m)

Depreciation and Amortization

923.0k295.0k594.0k892.0k276.0k565.0k854.0k286.0k569.0k843.0k

Inventories

1.2m1.2m197.0k6.0k

Accounts Payable

212.0k1.3m138.0k1.5m(184.0k)321.0k123.0k837.0k(90.0k)(264.0k)(491.0k)(655.0k)
USDFY, 2016

Revenue/Employee

4.9k

Financial Leverage

1.1 x
Show all financial metrics

Otonomy Operating Metrics

FY, 2016

Patents Issued

88

Patents Pending

115

Phase III Trials Products

2

Products

1
Show all operating metrics

Otonomy Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Otonomy Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Otonomy Online and Social Media Presence

Embed Graph

Otonomy News and Updates

Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus

SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 2 clinical trial of OTO-313 in patients with unilateral tinnitus. The randomize…

Otonomy to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management will participate in three upcoming virtual conferences:

Otonomy stock loses half its value after disappointing trial results of vertigo treatment

Shares of Otonomy Inc. plunged 50.1% to pace all premarket decliners, after the biopharmaceutical company said Phase 3 trial of its Ménière's disease (vertigo) treatment failed to meet its primary endpoint. "We are disappointed by the top-line results for the primary intent-to-treat population and …

Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the Phase 3 clinical trial of OTIVIDEX in patients with Ménière’s disease did not achieve the primary…

Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. ET

Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2020 and provide a corporate update …
Show more

Otonomy Blogs

Otonomy to Participate in Four Upcoming Investor Conferences

Otonomy to Participate in Four Upcoming Investor Conferences Content Import Wed, 09/02/2020 - 07:30 Otonomy to Participate in Four Upcoming Investor Conferences September 2, 2020 at 7:30 AM EDT This release is a backfill from a News Wire General…

Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update

Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update Content Import Tue, 07/28/2020 - 16:06 Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update July 28, 2020 at 4:05 PM EDT This release is a back…

Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Content Import Mon, 07/13/2020 - 16:01 Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Ju…

Otonomy Announces Pricing of $60.1 Million Public Offering

SAN DIEGO , July 09, 2020 (GLOBE NEWSWIRE) -- Otonomy , Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pricing of an underwritten public offering of 14,500,000 shares of its common stock at a price to the

Otonomy Announces Proposed Public Offering

SAN DIEGO , July 08, 2020 (GLOBE NEWSWIRE) -- Otonomy , Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it has commenced an underwritten public offering of its common stock.

Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus

Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus Content Import Mon, 07/06/2020 - 16:04 Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus July 6, 2020 at 4:…
Show more

Otonomy Frequently Asked Questions

  • When was Otonomy founded?

    Otonomy was founded in 2008.

  • Who are Otonomy key executives?

    Otonomy's key executives are David A. Weber, Carla da Luz Boren and Julie D. Burgess.

  • How many employees does Otonomy have?

    Otonomy has 49 employees.

  • What is Otonomy revenue?

    Latest Otonomy annual revenue is $273 k.

  • What is Otonomy revenue per employee?

    Latest Otonomy revenue per employee is $5.6 k.

  • Who are Otonomy competitors?

    Competitors of Otonomy include Seed Health, BeyondSpring and Alembic Pharmaceuticals.

  • Where is Otonomy headquarters?

    Otonomy headquarters is located at 4796 Executive Dr, San Diego.

  • Where are Otonomy offices?

    Otonomy has an office in San Diego.

  • How many offices does Otonomy have?

    Otonomy has 1 office.